Suppr超能文献

对短链神经酰胺诱导的抗增殖作用产生抗性与子宫颈癌细胞中葡糖神经酰胺合酶、P-糖蛋白和多药耐药基因-1的增加有关。

Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells.

作者信息

Gutiérrez-Iglesias Gisela, Hurtado Yamilec, Palma-Lara Icela, López-Marure Rebeca

机构信息

Laboratorio de Medicina Regenerativa y Estudios en Cáncer, Escuela Superior de Medicina, Instituto Politécnico Nacional, México, México.

出版信息

Cancer Chemother Pharmacol. 2014 Oct;74(4):809-17. doi: 10.1007/s00280-014-2552-3. Epub 2014 Aug 12.

Abstract

PURPOSE

Ceramide is glycosylated to glucosylceramide or lactosylceramide, and this glycosylation is a novel multidrug-resistance (MDR) mechanism. In this work, a short-chain ceramide (C6), lactosylceramide (LacCer), and an inhibitor of ceramide glycosylation (D-threo-1-phenyl-2-decanoylamino-3-1-propanol, PDMP) were evaluated on the proliferation of cervical cancer cells. The participation of glucosylceramide synthase (GCS), P-glycoprotein (P-gp), and multidrug-resistance gene-1 (MDR-1) in the resistance to the antiproliferative effect induced by C6 was also evaluated.

METHODS

Cell proliferation was determined by crystal violet staining. GCS and MDR-1 mRNA expression was evaluated by real-time RT-PCR assay. GCS and P-gp protein expressions, as well as Rhodamine 123 uptake, which is a functional test for P-gp efflux activity, were determined by flow cytometry.

RESULTS

C6 inhibited proliferation of CaLo and CasKi cells with an IC₅₀ of 2.5 μM; however, 50% proliferation of ViBo cells was inhibited with 10 μM. LacCer increased the proliferation of all cells. When cells were treated with PDMP plus C6, no additional effect on antiproliferation induced by C6 was observed in CaLo and CasKi cells; however, proliferation diminished in comparison with C6 alone in ViBo cells. C6 increased GCS and MDR-1 expression in all cells, as well as P-gp expression in CasKi cells.

CONCLUSIONS

Cells that have more capacity to glycosylate ceramide and express a higher level of GCS, MDR-1, and P-gp, are more resistant to the antiproliferative effect induced by C6.

摘要

目的

神经酰胺可糖基化为葡萄糖神经酰胺或乳糖神经酰胺,这种糖基化是一种新的多药耐药(MDR)机制。在本研究中,评估了短链神经酰胺(C6)、乳糖神经酰胺(LacCer)以及神经酰胺糖基化抑制剂(D-苏式-1-苯基-2-癸酰氨基-3-1-丙醇,PDMP)对宫颈癌细胞增殖的影响。还评估了葡萄糖神经酰胺合酶(GCS)、P-糖蛋白(P-gp)和多药耐药基因-1(MDR-1)在对C6诱导的抗增殖作用的耐药性中的参与情况。

方法

通过结晶紫染色测定细胞增殖。通过实时逆转录聚合酶链反应(RT-PCR)检测GCS和MDR-1 mRNA表达。通过流式细胞术测定GCS和P-gp蛋白表达以及罗丹明123摄取,后者是P-gp外排活性的功能测试。

结果

C6抑制CaLo和CasKi细胞的增殖,半数抑制浓度(IC₅₀)为2.5 μM;然而,10 μM的C6可抑制ViBo细胞50%的增殖。LacCer增加了所有细胞的增殖。当细胞用PDMP加C6处理时,在CaLo和CasKi细胞中未观察到对C6诱导的抗增殖作用有额外影响;然而,与单独使用C6相比,ViBo细胞中的增殖减少。C6增加了所有细胞中GCS和MDR-1的表达以及CasKi细胞中P-gp的表达。

结论

具有更强神经酰胺糖基化能力且表达更高水平的GCS、MDR-1和P-gp的细胞,对C6诱导的抗增殖作用更具抗性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验